On Monday, Shares of Novavax, Inc. (NASDAQ:NVAX), added 4.44% and closed at $1.88 in the last trading session. The last trading range of the stock ranges between $1.76 and $1.92. The company’s Market capitalization is $488.14 million with the total Outstanding Shares of 271.19 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.16 and reached to max level of $9.23. Novavax, Inc., (NVAX) recently declared it has replanned its 4th annual Shareholder and Analyst Meeting. The Company will host an Shareholder and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.
“We continue to analyze data from our Resolve clinical trial and map out the clinical path forward for our older adult RSV F Vaccine in the context of our other clinical programs,” said Stanley C. Erck, President and CEO. “We would like to finalize those plans and communicate them at the same time as our third quarter financial results call in early November. We look forward to providing the next steps in our RSV F Vaccine program, in addition to an update on the path forward for additional programs in our pipeline and our financial and operating plan, which we will provide as a dedicated part of our November financial results.”
Metlife Inc (NYSE:MET), jumped 0.76% and closed at $47.58 in the last trading session. The last trading range of the stock ranges between $47.32 and $47.80. During the 52-week trading session the minimum price at which share price traded, registered at $35.00 and reached to max level of $52.45. A.M. Best has removed from under review with developing implications and affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “aa-” of the Metropolitan Life Insurance Company (MLIC) (New York, NY), General American Life Insurance Company (St. Louis, MO) and Metropolitan Tower Life Insurance Company (Wilmington, DE) (collectively called RemainCo). In Addition To, the Long-Term ICR of “a-” of MetLife, Inc. (MetLife) (headquartered in New York, NY) [NYSE: MET] and its existing Long-Term Issue Credit Ratings have been removed from under review and affirmed.
Conpresently, A.M. Best has removed from under review with developing implications and downgraded the FSR to A (Excellent) from A+ (Superior) and the Long-Term ICR to “a+” from “aa-” of MetLife Insurance Company USA (Wilmington, DE), New England Life Insurance Company (Boston, MA) and First MetLife Shareholders Insurance Company (New York, NY). These entities (collectively referred to as Brighthouse) will be held under Brighthouse Financial, Inc., a newly formed holding company.
A.M. Best also has removed from under review with developing implications and affirmed the FSR of A (Excellent) and the Long-Term ICRs of “a+” of MetLife’s property/casualty companies, consisting of Metropolitan Property and Casualty Insurance Company, and seven fully reinsured auxiliaries, in addition to a separately rated partner, Metropolitan Group Property and Casualty Insurance Company (both domiciled in Warwick, RI) (together referred to as MetLife Auto & Home).